Back to top
more

BioRad Laboratories (BIO)

(Delayed Data from NYSE)

$368.42 USD

368.42
284,333

+10.23 (2.86%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $367.63 -0.79 (-0.21%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Cardiovascular Systems (CSII) in Focus: Stock Moves 8.4% Higher

Cardiovascular Systems, Inc. (CSII) was a big mover last session, as the company saw its shares rise over 8% on the day.

    Bio-Rad (BIO) Scores a Strong Buy Right Now: Here's How

    Bio-Rad Laboratories, Inc. (BIO) has rallied 12.9% over the last three months, ahead of the S&P 500's 4.3% gain.

      Health Care Battle Rages On: 2 MedTech Stocks to Buy

      Let's focus on two MedTech Stocks which are fundamentally strong amidst the volatile market condition.

        Capital Senior Living (CSU) in Focus: Stock Moves 5.8% Higher

        Capital Senior Living Corporation (CSU) was a big mover last session, as the company saw its shares rise almost 6% on the day.

          Omeros (OMER) Worth a Look: Stock Adds 11.8% in Session

          Omeros Corporation (OMER) shares rose almost 12% in the last trading session.

            What Falling Estimates & Price Mean for Eagle Pharmaceuticals (EGRX)

            Eagle Pharmaceuticals (EGRX) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

              Imprimis Pharmaceuticals (IMMY) Looks Good: Stock Up 13%

              Imprimis Pharmaceuticals, Inc. (IMMY) shares rose over 13% in the last trading session.

                David Bartosiak headshot

                Five Stocks Rocketing Higher on Huge Momentum

                The bears were sent running, screaming towards their caves today as the market started strong and didn???t look back at all

                  TransEnterix (TRXC) Reports Wider-than-Expected Loss in Q1

                  TransEnterix, Inc. (TRXC) reported a loss of 13 cents per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 12 cents.

                    Masimo (MASI) Beats on Q1 Earnings and Revenues, Guides Up

                    Masimo Corp. (MASI) reported earnings of 57 cents per share in the first quarter of 2017, outperforming the Zacks Consensus Estimate of 54 cents and improving from the year-ago quarterly earnings of 53 cents.

                      Medtronic (MDT) Wins FDA Approval for CRT-P SureScan Suite

                      Medtronic plc (MDT) recently won FDA approval for a portfolio of quadripolar cardiac resynchronization therapy-pacemakers that improve therapy delivery for patients with heart failure.

                        STERIS (STE) Grapples with Headwinds: Should You Dump?

                        On May 10, we issued an updated research report on STERIS Plc (STE) which manufactures and markets infection prevention, decontamination, microbial reduction, and surgical and gastrointestinal support products and services.

                          Hologic (HOLX) Tops Q2 Earnings & Sales, Raises 2017 View

                          Hologic Inc. (HOLX) reported second-quarter fiscal 2017 adjusted earnings per share (EPS) of 50 cents, up 6.4% year over year.

                            Genomic Health (GHDX) Misses Q1 Earnings & Sales Estimates

                            Genomic Health, Inc. (GHDX) reported first-quarter 2017 loss per share of 7 cents, reflecting an improvement from the year-ago quarter's loss figure of 19 cents.

                              Dull Q1 Earnings & Tough Industry Spell Trouble for BioScrip

                              On May 10, we issued an updated research report on BioScrip, Inc. (BIOS ), a pure-play Infusion Service provider.

                                Becton (BDX) Announces $4.5B Follow-On Share Offerings

                                Becton, Dickinson and Company (BDX), popularly known as BD, recently announced a follow-on offering of $4.5 billion for its shares.

                                  STERIS (STE) Tops Q4 Earnings & Revenues, Issues '18 View

                                  STERIS Plc (STE) reported fourth-quarter fiscal 2017 adjusted earnings per share (EPS) of $1.11, up 23.3% from the year-ago quarter.

                                    Tirthankar Chakraborty headshot

                                    New Strong Buy Stocks for May 9th

                                    Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday

                                      Medical Product Stocks' Earnings Due on May 4: ABMD & More

                                      Here we discuss four major Medical Product bigwigs, which are scheduled to release their earnings results on May 4.

                                        MedTech Stocks' Earnings Due on Feb 23: TFX, SAUHF, BIO, PDCO

                                        Let's take a look at the major MedTech stocks slated to release their Oct-Dec 2016 numbers on Feb 23.

                                          New Strong Sell Stocks for February 17th

                                          Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: